SILENT CEREBRAL INFARCT MULTI-CENTER TRIAL

无症状脑梗死多中心试验

• 批准号: 7608351
• 负责人: CATERINA MINNITI
• 金额: $ 2.64万
• 依托单位: CHILDREN'S RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7608351
• 关键词: Blood Transfusion; Brain; Brain imaging; Cerebrum; Child; Childhood Injury; Computer Retrieval of Information on Scientific Projects Database; Effectiveness; Focal Neurologic Deficits; Frequencies; Funding; Grant; Hour; Image; Infarction; Institution; Ischemic Brain Injury; Magnetic Resonance Imaging; Measures; Morbidity - disease rate; Motor; Neurologic; Patients; Prevention therapy; Purpose; Recording of previous events; Relative (related person); Research; Research Personnel; Resources; Risk; Sickle Cell Anemia; Signal Transduction; Source; Stroke; Transfusion; United States National Institutes of Health; Weight; cognitive function; experience; mortality; motor deficit

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The major cause of morbidity and mortality in sickle cell anemia is vaso-occlusion. Cerebral infarcts in children with sickle cell anemia may impair motor and/or cognitive function. Overt strokes occurring in patients with sickle cell anemia have been characterized by a sudden and persistent onset of motor deficits, resulting in clear recognition and prompt treatment. However, silent cerebral infarcts, defined as an abnormal MRI image of the brain with increased signal intensity in multiple T2 weighted images and no history or physical finding of a focal neurologic deficit lasting more than 24 hours, are the most common form of neurologic injury in children with sickle cell anemia. The only proven therapy for prevention of overt strokes in children with sickle cell anemia who have already had strokes is blood transfusion therapy. Without blood transfusion, patients who have experienced strokes have approximately a 70% risk of a second stroke. With transfusion therapy, there is at least and 85% relative reduction in the frequency of subsequent strokes. The purpose of this study is to determine the effectiveness of blood transfusion therapy for the prevention of new ischemic brain injury in the form of overt stroke or silent cerebral infarct measured by MRI of the brain.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 镰状细胞性贫血发病和死亡的主要原因是血管闭塞。镰状细胞性贫血儿童的脑梗塞可能会损害运动和/或认知功能。镰状细胞性贫血患者发生的明显中风的特点是突然且持续的运动缺陷，从而导致明确的识别和及时的治疗。然而，无症状性脑梗死是镰状细胞性贫血儿童最常见的神经损伤形式，其定义为大脑 MRI 图像异常，多个 T2 加权图像中信号强度增加，并且没有病史或体格发现持续超过 24 小时的局灶性神经功能缺损。 对于已经患有中风的镰状细胞性贫血儿童，唯一经过验证的预防明显中风的疗法是输血疗法。如果没有输血，经历过中风的患者大约有 70% 的风险会发生第二次中风。通过输血治疗，后续中风的频率相对减少至少 85%。本研究的目的是确定输血疗法对于预防新的缺血性脑损伤（通过大脑 MRI 测量的明显中风或无症状脑梗塞）的有效性。